A detailed history of Alpha Mark Advisors, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Alpha Mark Advisors, LLC holds 1,725 shares of KRYS stock, worth $305,135. This represents 0.11% of its overall portfolio holdings.

Number of Shares
1,725
Previous 1,922 10.25%
Holding current value
$305,135
Previous $353,000 11.05%
% of portfolio
0.11%
Previous 0.12%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

SELL
$174.7 - $213.66 $34,415 - $42,091
-197 Reduced 10.25%
1,725 $314,000
Q2 2024

Jul 17, 2024

BUY
$153.12 - $183.64 $294,296 - $352,956
1,922 New
1,922 $353,000
Q2 2022

Aug 11, 2022

BUY
$48.93 - $73.47 $489 - $734
10 New
10 $1,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.54B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Alpha Mark Advisors, LLC Portfolio

Follow Alpha Mark Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Mark Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Mark Advisors, LLC with notifications on news.